| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 28.421 | 9.994 | 0 | 0 | 10.305 | 15.718 | 829 | 3.042 | 30.630 | 23.782 |
| Total Income - EUR | 28.421 | 9.994 | 0 | 0 | 10.305 | 15.718 | 829 | 3.042 | 30.630 | 23.900 |
| Total Expenses - EUR | 11.382 | 9.257 | 188 | 9 | 8.226 | 17.492 | 13.617 | 10.819 | 30.485 | 40.239 |
| Gross Profit/Loss - EUR | 17.038 | 737 | -188 | -9 | 2.078 | -1.774 | -12.788 | -7.777 | 145 | -16.339 |
| Net Profit/Loss - EUR | 16.186 | 437 | -188 | -9 | 1.975 | -1.932 | -12.797 | -7.808 | 67 | -16.339 |
| Employees | 1 | 1 | 1 | 0 | 2 | 2 | 2 | 1 | 3 | 3 |
Check the financial reports for the company - Biotec Apidav Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18.763 | 13.683 |
| Current Assets | 31.690 | 21.283 | 20.766 | 20.317 | 24.643 | 24.996 | 14.415 | 2.053 | 6.718 | 553 |
| Inventories | 0 | 0 | 0 | 516 | 506 | 496 | 485 | 0 | 0 | 0 |
| Receivables | 8.384 | 1.552 | 1.525 | 982 | 963 | 944 | 923 | 0 | 0 | 31 |
| Cash | 23.306 | 19.731 | 19.241 | 18.820 | 23.175 | 23.556 | 13.006 | 2.053 | 6.718 | 522 |
| Shareholders Funds | 15.687 | 15.964 | 15.506 | 15.212 | 16.893 | 14.641 | 1.520 | -6.283 | -6.197 | -22.501 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 16.003 | 5.319 | 5.260 | 5.105 | 7.750 | 10.355 | 12.895 | 8.336 | 31.678 | 36.737 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4120 - 4120" | |||||||||
| CAEN Financial Year |
4120
|
|||||||||
Comments - Biotec Apidav Srl